Mirogabalin

Mirogabalin is a gabapentinoid medication developed by Daiichi Sankyo. Gabapentin and pregabalin are also members of this class. As a gabapentinoid, mirogabalin binds to the α₂δ subunit of voltage-gated calcium channel, but with significantly higher potency than pregabalin. It has shown promising results in Phase II clinical trials for the treatment of diabetic peripheral neuropathic pain.
Phase III trial results:

Effective: for post-herpetic neuralgia
Ineffective: for fibromyalgia
Effective: for diabetic peripheral neuropathic pain

In Japan, the company submitted a marketing application for treatment of peripheral neuropathic pain. The medication was approved for neuropathic pain and postherpetic neuralgia in Japan in January 2019.